STL Index for: TCS
Psoriasis types and subtypes can influence preferred treatment modality. This article discusses the symptoms specific to the psoriasis subtype, and considerations for selecting treatment.
Topical corticosteroid dosing, mechanism of action and prescribing advice is provided in this article. General rules, prescribing suggestions, precautions, and side-effects are discussed.
Dovobet®/ Daivobet®/ Taclonex® is a product combining two molecules, calcipotriol and betamethasone dipropionate, that may offer psoriatic patients with an option for maintenance therapy. The efficacy and safety of this combined formulation when used over a 4-week period is well documented.
This article summarizes the clinical indications and findings of Cutivate (Fluticasone Propionate). Guidelines are also provided for treating atopic dermatitis.
An in depth second part to the side-effects, safety and risks associated with Eumovate (Clobetasone Butyrate). Allergies, local, and systemic side-effects are discussed.
Eumovate (Clobetasone Butyrate), patient profiles, dosing, efficacy, and compliance issues are discussed as well as a comparison in vehicles between cream and ointment.
A review of corticosteroids, including use, adverse effects, vehicle, generic vs brand name drugs. Physicians and pharmacists alike should be aware of the importance and the difference of various vehicles when prescribing topical corticosteroids.
Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.
Eumovate (Clobetasone Butyrate) and their uses in treating a variety of skin conditions are discussed - clinical experience and indications. Conditions include atopic dermatitis, lichen planus, psoriasis, and seborrheic dermatitis.
Atopic dermatitis is a highly pruritic inflammatory disorder of the skin characterized by onset in infancy or childhood and a chronically relapsing course. Mainstay treatments are emollients and topical corticosteroids, but the latter are limited by side-effects from longterm use.
Prednicarbate is a nonhalogenated corticosteroid that is used in the treatment of inflammatory skin diseases, for example atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.
Tacrolimus ointment (Protopic®, Fujisawa) is an effective agent in a class of topical immunomodulators. It has been shown to be safe and effective in adults and children with Atopic Dermatitis in short- and long-term treatments.
The exact mechanism of action of leukotriene receptor antagonists in Atopic Dermatitis is not known. In small clinical and case studies, montelukast was found to be a safe and effective alternative or steroid-sparing therapy in the management of patients with atopic dermatitis.
Psoriasis is a common dermatosis, affecting children in North America. Many papers have stressed the treatments available for adult psoriasis, but few have dealt with this disorder in children. Topical treatment modalities continue to be the first line therapy for childhood psoriasis.
Use of medications by breast-feeding mothers is not uncommon. Information regarding the safety of common dermatological medications during lactation will be reviewed. Based on this information, treatment recommendations will be made.
Toxicodendron dermatitis results from a reaction to an oil soluble oleoresin that is present in many parts of the poison ivy and poison oak plants. Prophylactic measures and treatments are discussed.
With growing public reluctance to use systemic medications we can expect topical treatments for psoriasis and other skin conditions to become increasingly important in the future. These drugs are useful not only to control this disease, but also to limit the irritation caused by medications such as tazarotene and anthralin.
Corticosteroids have dominated the class of anti-inflammatory agents for the past 50 years. In the last ten years, new corticosteroids have been developed for topical use. Characteristics common to these several chemically different corticosteroids are their class III, or high potency designation and their improved safety profile.
12Page 2 of 2